

Robert Gray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5135901/publications.pdf>

Version: 2024-02-01

36
papers

15,156
citations

331670

21
h-index

377865

34
g-index

37
all docs

37
docs citations

37
times ranked

27976
citing authors

#	ARTICLE	IF	CITATIONS
1	A Proportional Hazards Model for the Subdistribution of a Competing Risk. <i>Journal of the American Statistical Association</i> , 1999, 94, 496-509.	3.1	10,534
2	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 111-121.	27.0	1,558
3	Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System. <i>Journal of Clinical Oncology</i> , 2007, 25, 2127-2132.	1.6	709
4	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 559-569.	1.6	505
5	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2395-2405.	27.0	349
6	Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3938-3944.	1.6	223
7	Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). <i>Journal of Clinical Oncology</i> , 2020, 38, 3883-3894.	1.6	168
8	Prognostic Value of Histologic Grade and Proliferative Activity in Axillary Node-Positive Breast Cancer: Results From the Eastern Cooperative Oncology Group Companion Study, EST 4189. <i>Journal of Clinical Oncology</i> , 2000, 18, 2059-2069.	1.6	147
9	Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> ^{V600E} Mutations: Results of the NCI-MATCH Trial Subprotocol H. <i>Journal of Clinical Oncology</i> , 2020, 38, 3895-3904.	1.6	145
10	The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1021-1029.	6.3	138
11	Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy. <i>JAMA Oncology</i> , 2020, 6, 367.	7.1	100
12	Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 557-564.	1.6	69
13	Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 390-399.	6.3	62
14	Effect of Capivasertib in Patients With an <i>AKT1</i> E17K-Mutated Tumor. <i>JAMA Oncology</i> , 2021, 7, 271.	7.1	49
15	Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring <i>BRAF</i> Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). <i>Clinical Cancer Research</i> , 2020, 26, 1812-1819.	7.0	47
16	Weighted analyses for cohort sampling designs. <i>Lifetime Data Analysis</i> , 2009, 15, 24-40.	0.9	46
17	A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG) Tj ETQq1.1 0.784314 rgBT		
18	Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. <i>British Journal of Cancer</i> , 2014, 111, 1241-1248.	6.4	37

#	ARTICLE	IF	CITATIONS
19	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 3.	5.2	33
20	Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation. <i>JAMA Oncology</i> , 2022, 8, 579.	7.1	27
21	Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. <i>Journal of Clinical Oncology</i> , 2022, 40, 1552-1561.	1.6	26
22	Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i> -Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i> -Mutated Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2996-3004.	7.0	23
23	Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial. <i>Cancer</i> , 2021, 127, 2545-2552.	4.1	20
24	Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. <i>Npj Precision Oncology</i> , 2022, 6, 13.	5.4	18
25	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.	2.9	15
26	Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1360-1369.	6.3	14
27	High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	3.0	11
28	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz049.	2.9	11
29	Phase II Study of Taselisib in <i>PIK3CA</i> -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. <i>JCO Precision Oncology</i> , 2022, 6, e2100424.	3.0	9
30	Estimating Treatment Effect in a Proportional Hazards Model in Randomized Clinical Trials with All-or-Nothing Compliance. <i>Biometrics</i> , 2016, 72, 742-750.	1.4	8
31	TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps. <i>Journal of Clinical Oncology</i> , 2019, 37, 1841-1842.	1.6	5
32	Pragmatic approaches to address expansion cohort design. <i>Cancer</i> , 2018, 124, 3290-3292.	4.1	2
33	Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz062.	2.9	2
34	Noninferiority trials with nonadherence to the assigned randomized treatment. <i>Clinical Trials</i> , 2019, 16, 673-681.	1.6	1
35	Abstract GS4-10: Development and validation of a tool integrating the 21-gene recurrence score and clinicopathologic features to individualize prognosis for distant recurrence and prediction of absolute chemotherapy benefit in early breast cancer. , 2021, , .		0
36	Reply to K. Ando et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 1947-1948.	1.6	0